Cite
HARVARD Citation
Forsyth, S. et al. (2022). Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial. Clinical pharmacology in drug development. 11 (5), pp. 654-665. [Online].